

Supplementary Table 1. The use of anti-diabetic agents before hospitalization stratified by sex

Anti-diabetic agents, <i>n</i> (%)	Total N = 284	Male N = 178	Female N = 106	<i>P</i>
Oral anti-diabetes drugs				
Metformin	164 (57.7)	102 (57.3)	62 (58.5)	0.845
Sulfonylureas	73 (25.7)	51 (28.7)	22 (20.8)	0.141
Thiazolidinediones	21 (7.4)	11 (6.2)	10 (9.4)	0.311
Glinides	24 (8.5)	16 (9.0)	8 (7.5)	0.673
DPP-4 inhibitors	2 (0.7)	1 (0.6)	1 (0.9)	1.000
GLP-1 receptor agonist	39 (13.7)	23 (12.9)	16 (15.1)	0.607
Insulin				
CSII	1 (0.4)	1 (0.6)	0 (0.0)	1.000
Long-acting insulin merely	23 (8.1)	19 (10.7)	4 (3.8)	0.039
Premixed insulin twice daily	108 (38.0)	62 (34.8)	46 (43.4)	0.150
Premixed insulin 3 times daily	5 (1.8)	4 (2.2)	1 (0.9)	0.733
Intensive therapy	13 (4.6)	8 (4.5)	5 (4.7)	1.000

Data were expressed as *n* (%).

Abbreviation: CSII: continuous subcutaneous insulin infusion; DPP-4: Dipeptidyl peptidase-4; GLP-1: Glucagon-like peptide-1.

Supplementary Table 2. The use of anti-diabetic agents during hospitalization stratified by sex

Anti-diabetic agents, <i>n</i> (%)	Total N = 284	Male N = 178	Female N = 106	<i>P</i>
Oral anti-diabetes drugs				
Metformin	134 (47.2)	80 (44.9)	54 (50.9)	0.327
Sulfonylureas	40 (14.1)	28 (15.7)	12 (11.3)	0.301
Thiazolidinediones	11 (3.9)	6 (3.4)	5 (4.7)	0.802
Glinides	17 (6.0)	10 (5.6)	7 (6.6)	0.735
DPP-4 inhibitors	30 (10.6)	19 (10.7)	11 (10.4)	0.793
GLP-1 receptor agonist	1 (0.4)	0 (0.0)	1 (0.9)	0.937
Insulin				
CSII	112 (39.4)	72 (40.4)	40 (37.7)	0.651
Long-acting insulin merely	12 (4.2)	11 (6.2)	1 (0.9)	0.069
Premixed insulin twice daily	53 (18.7)	31 (17.4)	22 (20.8)	0.485
Premixed insulin 3 times daily	1 (0.4)	0 (0.0)	1 (0.9)	0.793
Intensive therapy	22 (7.7)	13 (7.3)	9 (8.5)	0.717

Data were expressed as *n* (%).

Abbreviation: CSII: continuous subcutaneous insulin infusion; DPP-4: Dipeptidyl peptidase-4; GLP-1: Glucagon-like peptide-1.

Supplementary Table 3. Adjusted associations of CGI and AUC_{CP30}/AUC_{PG30} with saliva/serum 1,5-AG.

	β (95% Confidence interval)	<i>P</i>
Total group (n = 284; adjusted for OHA treatment before hospitalization)		
Saliva 1,5-AG		
CGI	0.135 (0.021–0.248)	0.020
AUC _{CP30} /AUC _{PG30}	0.107 (0.004–0.209)	0.041
Serum 1,5-AG		
CGI	0.256 (0.141–0.371)	< 0.001
AUC _{CP30} /AUC _{PG30}	0.387 (0.290–0.483)	< 0.001
Total group (n = 284; adjusted for OHA treatment after hospitalization)		
Saliva 1,5-AG		
CGI	0.135 (0.023–0.247)	0.018
AUC _{CP30} /AUC _{PG30}	0.126 (0.032–0.221)	0.009
Serum 1,5-AG		
CGI	0.217 (0.094–0.329)	0.001
AUC _{CP30} /AUC _{PG30}	0.311 (0.211–0.410)	< 0.001

Abbreviation: 1,5-AG: 1,5-anhydroglucito; AUC_{CP30}/AUC_{PG30}: ratio of 0-30 minutes area under the curve for C-peptide and area under the curve for glucose; CGI: C-peptidogenic index; OHA: oral hypoglycemic agents.